Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Eiichi ArakiChantal MathieuToshihiko ShiraiwaHajime MaedaHiroki IkedaFredrik ThorenNiki AryaMichiko AsanoNayyar IqbalPublished in: Diabetes, obesity & metabolism (2021)
Efficacy and safety results from the Japanese subpopulation of the DEPICT-2 study were generally consistent with those from the overall population, indicating that long-term dapagliflozin adjunct to insulin therapy improves glycaemic control without an increased risk of hypoglycaemia but with a risk of diabetic ketoacidosis in Japanese patients with type 1 diabetes.